Inhibition of tumour necrosis factor-alpha in patients with chronic hepatitis C infection.
Zavos
C
C
Kountouras
J
J
Zavos
N
N
Chatzopoulos
D
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D018450:Disease Progression; D016174:Hepacivirus / Q000187:drug effects / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000821:virology; D008103:Liver Cirrhosis / Q000276:immunology / Q000473:pathology / Q000821:virology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014775:Virus Activation / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha